MNT: RDN in Medical Team (2015)
Cueto-Manzano AM, Martinex-Ramirez HR, Cortes-Sanabria L. Management of chronic kidney disease: Primary health-care setting, self-care and multidisciplinary approach. Clin Neph. 2010; 74(Suppl): S99-S104.
PubMed ID: 20979973- Diabetes mellitus
- Hypertension
- Overweight or obesity.
Recruitment
Existing adult patients in the family medical practice who were not in control of diabetes mellitus, hypertension or overweight/obesity were invited to participate.
Design
Prospective cohort study with identified participants receiving defined multi-disciplinary and multi-pronged intervention over a six-month period.
Intervention
- Participants received weekly two-hour educational intervention for four weeks with:
- Emotional management conducted by a social worker
- Nutritional patterns with a dietitian
- Exercise with a physical trainer
- Health-related problems with a family physician.
- After the first four weeks, participants were seen every three months for assessment of goal achievements and every month with the physician for a regular visit. In addition, the subjects were divided into smaller groups of 20 people with a leader selected to coordinate, motivate and encourage the members of the group.
Statistical Analysis
Software was not specified but provided data includes mean, range and significance of P<0.05.
Timing of Measurements
Measurements were taken at baseline, three months and six months
Dependent Variables
- Lifestyle questionnaire score including sectional components of knowledge and adherence, emotions, exercise, tobacco consumption, alcohol consumption and diet (total maximum healthy score 84)
- Systolic blood pressure (mm Hg)
- Diastolic blood pressure (mm Hg)
- Body mass index (kg/m2)
- Waist circumference (cm)
- Glucose (mg per dL)
- LDL-cholesterol (mg per dL)
- Triglycerides (mg per dL)
- Glomerular filtration rate (GFR) (ml per minute per 1.73m2)
- Albuminuria (mg per 24 hours).
Independent Variables
- Age
- Gender
- Illiteracy
- Smoking
- Alcohol intake.
- Initial N: N=184 patients
- Attrition (final N): N=184 patients
- Age: See table
- Ethnicity: Mexico.
Other Relevant Demographics:
Diabetes Mellitus | Hypertension | Overweight or Obesity | |
Patients, N | 88 | 45 | 51 |
Age, years | 54±10 | 54±12 | 43±13 |
Female, N (%) | 66 (75) | 28 (62) | 44 (86) |
Illiteracy, N (%) | 9 (10) | 1 (8) | 1 (2) |
Smoking, N (%) | 7 (8) | 2 (4) | 4 (8) |
Alcohol intake, N (%) | 14 (16) | 5 (11) | 9 (18) |
Anthropometrics
Age was significantly lower in the overweight and obesity group.
Location
Guadalajara, Jalisco, Mexico.
Key Findings
- All groups reported a notable improvement in nutritional and exercise habits, as well as in management of their emotions and total score in the lifestyle questionnaire
- Diabetics and hypertensives significantly improved the knowledge of their disease and adherence to treatment
- Diabetics significantly reduced body mass index, waist circumference and blood glucose and increased GFR
- Hypertensive patients significantly decreased systolic blood pressure, body mass index and waist circumference
- Overweight and obese patients significantly decreased body mass index, waist circumference and blood glucose, and increased GFR
- All observed changes were independent of pharmacological treatment, as medication regimens did not change over the course of the study.
Variable | DM Baseline | DM Final | HTN Baseline | HTN Final | Obese Baseline | Obese Final |
Lifestyle questionnaire | 51.8±10.1 | 65.4±9.0 | 54.7±10.2 | 67.0±8.0 | 52.8±8.9 | 66.1±8.2 |
Systolic BP (mm Hg) | 129±19 | 124±12 | 145±3 | 130±18 | 117±11 | 120±11 |
Diastolic BP (mm Hg) | 79±12 | 77±10 | 85±11 | 80±9 | 76±9 | 76±7 |
BMI (kg/m2) | 34.0±6.4 | 33.1±6.3 | 35.6±5.2 | 33.9±5.7 | 35.4± 5.0 | 33.3±5.1 |
Waist circumference (cm) | 103±12 | 102±13 | 109±11 | 104±12 | 106±13 | 100±10 |
Glucose (mg per dL) | 170±65 | 148±52 | 114±30 | 110±23 | 100±13 | 98±12 |
LDL-cholesterol (mg per dL) | 112 (92 to 137) | 116 (96 to 140) | 122 (94 to 146) | 116 (92 to 157) | 112 (97 to 139) | 117 (86 to 142) |
Triglycerides (mg per dL) | 168 (129 to 223) | 166 (127 to 229) | 172 (126 to 259) | 147 (128 to 203) | 127 (95 to 189) | 135 (115 to 127) |
GFR (ml per minute per 1.73m2) | 99 (81 to 123) | 103 (86 to 128) | 99 (84 to 127) | 106 (81 to 147) | 116 (94 to 147) | 113 (87 to 150) |
Albuminuria (mg per 24 hours) | 6.3 (4.3 to 15.3) | 6.5 (4.5 to 12.4) | 5.6 (2.9 to 12.1) | 4.4 (3.8 to 10.4) | 5.8 (3.6 to 8.1) | 7.0 (4.2 to 9.0) |
University/Hospital: | Hospital de Especialidades, CMNO, IMSS, Guadalajara Mexico |
Quality Criteria Checklist: Primary Research
|
|||
Relevance Questions | |||
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
Validity Questions | |||
1. | Was the research question clearly stated? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.3. | Were the target population and setting specified? | Yes | |
2. | Was the selection of study subjects/patients free from bias? | No | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | Yes | |
2.2. | Were criteria applied equally to all study groups? | Yes | |
2.3. | Were health, demographics, and other characteristics of subjects described? | Yes | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | Yes | |
3. | Were study groups comparable? | Yes | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | Yes | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | Yes | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | N/A | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | Yes | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | N/A | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | Yes | |
4. | Was method of handling withdrawals described? | N/A | |
4.1. | Were follow-up methods described and the same for all groups? | Yes | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | Yes | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | Yes | |
4.4. | Were reasons for withdrawals similar across groups? | Yes | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | Yes | |
5. | Was blinding used to prevent introduction of bias? | No | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | No | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | Yes | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | No | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | No | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | Yes | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | Yes | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | Yes | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | Yes | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | No | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | Yes | |
6.6. | Were extra or unplanned treatments described? | Yes | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | Yes | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | Yes | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | Yes | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | Yes | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | Yes | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | Yes | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | Yes | |
7.7. | Were the measurements conducted consistently across groups? | Yes | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | ??? | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | No | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | ??? | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | Yes | |
10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
10.2. | Was the study free from apparent conflict of interest? | Yes | |